- Home
- TEVA
as 10-24-2025 3:50pm EST
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
| Founded: | 1901 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 21.2B | IPO Year: | N/A |
| Target Price: | $25.57 | AVG Volume (30 days): | 9.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.46 - $22.80 | Next Earning Date: | 11-05-2025 |
| Revenue: | $16,628,000,000 | Revenue Growth: | 2.08% |
| Revenue Growth (this year): | 4.37% | Revenue Growth (next year): | 0.67% |
Latest Teva Pharmaceutical Industries Limited News
TEVA Breaking Stock News: Dive into TEVA Ticker-Specific Updates for Smart Investing
Insider Monkey
5 days ago
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Simply Wall St.
6 days ago
Teva (TEVA) Gains FDA Approval for UZEDY Injectable in Bipolar I Disorder Treatment – What's Changed
Zacks
6 days ago
All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy
Zacks
6 days ago
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?
Zacks
6 days ago
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Zacks
6 days ago
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
Insider Monkey
6 days ago
Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy
Business Wire
6 days ago
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
Compare TEVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TEVA Teva Pharmaceutical Industries Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.